10% off your first order — code WELCOME10 · For research use only · Not for human consumption · All sales final
Home/Research/What Is Semaglutide? GLP-1 Research Peptide Overview
Apr 7, 2026 · Research use only

What Is Semaglutide? GLP-1 Research Peptide Overview

Semaglutide is the foundational single GLP-1 agonist in the metabolic cluster. Here's what it is, the GLP-1 receptor it targets, and how research uses it.

Semaglutide is the foundational compound in the GLP-1 metabolic research cluster — the single-receptor agonist that the dual and triple agonists are measured against. Understanding semaglutide is the starting point for understanding the whole class. This overview covers what semaglutide is, the receptor it targets, and its research context. For in-vitro laboratory research only.

Research-use-only: semaglutide is supplied as a research-grade reference standard for in-vitro laboratory research. It is not a drug, supplement, or product for human or veterinary use.

What is semaglutide?

Semaglutide is a synthetic GLP-1 receptor agonist — a peptide engineered to bind and activate a single incretin receptor, the GLP-1 receptor. It is the most established compound in the incretin-mimetic class used in metabolic research. The semaglutide research kit is supplied lyophilized in multi-vial research kits.

What receptor does semaglutide target?

Semaglutide is a single agonist: it targets the GLP-1 receptor (glucagon-like peptide-1) and that receptor only. The GLP-1 pathway is studied for its role in appetite-regulation models and glucose-dependent insulin-signaling. Because it engages just one receptor, semaglutide serves as the clean single-agonist baseline in receptor-pharmacology comparisons.

Where semaglutide sits in the cluster

The metabolic cluster is often described by receptor count, and semaglutide anchors the simplest tier:

  • Semaglutide — single agonist (GLP-1 only)
  • Tirzepatide — dual agonist (GIP + GLP-1)
  • Retatrutide — triple agonist (GIP + GLP-1 + glucagon)

For the direct head-to-head with the dual agonist, see semaglutide vs tirzepatide; for the full receptor map, see GLP-1 research peptides explained.

Semaglutide combinations in research

Beyond standalone study, semaglutide is investigated in combination with the amylin analog cagrilintide. The cagrilintide + semaglutide blend pairs an amylin-receptor agonist with the GLP-1 agonist so researchers can examine complementary metabolic pathways in a single preparation — covered in our cagrilintide + semaglutide explainer.

What is semaglutide studied for?

As a reference standard, semaglutide is used in GLP-1 receptor-binding and signaling assays and in metabolic models examining appetite-regulation and insulin-signaling pathways. Its long track record makes it the default control compound when researchers benchmark newer multi-receptor agonists.

How the research kit is supplied

Semaglutide ships lyophilized in multi-vial research kits from our US facility within 48 hours with tracking. Reconstitute with bacteriostatic water using the reconstitution calculator. Order the semaglutide reference standard or browse the full shop.

Frequently asked questions

What is semaglutide?

Semaglutide is a synthetic GLP-1 receptor agonist — a single-receptor incretin compound and the foundational member of the metabolic research cluster. It is supplied as a research-use-only reference standard.

What receptor does semaglutide target?

Only the GLP-1 receptor. That single-agonist profile is what distinguishes it from the dual agonist tirzepatide (GIP + GLP-1) and the triple agonist retatrutide (GIP + GLP-1 + glucagon).

Why is semaglutide combined with cagrilintide?

Cagrilintide is an amylin-receptor agonist, a different pathway from GLP-1. Pairing the two lets researchers study complementary metabolic mechanisms; it is supplied as the cagrilintide + semaglutide blend.